SCHEMBL4173693

SCHEMBL4173693

O=C(NCCCC(NC(=O)OCc1ccccc1)C(=O)O)OCc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 5/20 0.72
SIRT2 Q8IXJ6 1/20 0.64
SIRT1 Q96EB6 1/20 0.64
ITGB3 P05106 2/20 0.64
ITGAV P06756 2/20 0.64
HTT P42858 1/20 0.62
MMP2 P08253 1/20 0.61
MMP9 P14780 1/20 0.61
CPB1 P15086 1/20 0.60
CPB2 Q96IY4 1/20 0.60
TGM2 P21980 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11875673 1.00 FOLH1 (0.72) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL4173691 1.00 FOLH1 (0.72) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL464715 0.96 FOLH1 (0.78) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL806151 0.96 FOLH1 (0.78) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL4561005 0.96 FOLH1 (0.78) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL6946394 0.92 FOLH1 (0.65) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL18063383 0.92 FOLH1 (0.65) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL14157482 0.91 FOLH1 (0.72) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL18907028 0.91 FOLH1 (0.72) FOLH1SIRT2SIRT1ITGB3ITGAV
SCHEMBL18907025 0.91 FOLH1 (0.72) FOLH1SIRT2SIRT1ITGB3ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12426782-B2 Systems and temporal alignment methods for evaluation of gestational age and time to delivery THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-09-30 US claimed
US-20220142477-A1 Systems and Temporal Alignment Methods for Evaluation of Gestational Age and Time to Delivery THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-05-12 US claimed
EP-3988538-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) 2022-04-27 EP claimed
US-20220111055-A1 MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) 2022-04-14 US claimed
EP-3853613-A1 METHODS FOR EVALUATION OF GESTATIONAL PROGRESS AND PRETERM ABORTION FOR CLINICAL INTERVENTION AND APPLICATIONS THEREOF The Board of Trustees of the Leland Stanford Junior University (US) 2021-07-28 EP claimed
WO-2020252713-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF 浙江智达药业有限公司 2020-12-24 WO claimed
WO-2020061590-A1 METHODS FOR EVALUATION OF GESTATIONAL PROGRESS AND PRETERM ABORTION FOR CLINICAL INTERVENTION AND APPLICATIONS THEREOF THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-03-26 WO claimed
US-12616676-B2 Preparation method and use of modified hydrophobic excipient ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) 2026-05-05 US disclosed
US-12426782-B2 Systems and temporal alignment methods for evaluation of gestational age and time to delivery THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-09-30 US disclosed
EP-3988538-B1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) 2024-08-07 EP disclosed
US-11993571-B2 Indole derivatives as efflux pump inhibitors RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-05-28 US disclosed
US-20220142477-A1 Systems and Temporal Alignment Methods for Evaluation of Gestational Age and Time to Delivery THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-05-12 US disclosed
EP-3988538-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) 2022-04-27 EP disclosed
US-20160271082-A1 BACTERIAL EFFLUX PUMP INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-09-22 US disclosed
US-8324176-B2 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-12-04 US disclosed
EP-1548024-B1 PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF KISSEI PHARMACEUTICAL (JP) 2012-06-06 EP disclosed
US-7635684-B2 treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-22 US disclosed
US-20090203633-A1 PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF KISSEI PHARMACEUTICAL CO., LTD (JP) 2009-08-13 US disclosed
US-20050272669-A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-12-08 US disclosed
EP-1548024-A1 PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2005-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616676-B2 Preparation method and use of modified hydrophobic excipient CETP, LIPA, MTTP FOLH1 4283/4885SIRT2 2667/4885SIRT1 3042/4885
US-20090203633-A1 PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF UGGT1, GCKR, SLC5A1 FOLH1 2763/4885SIRT2 185/4885SIRT1 61/4885
US-20050272669-A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof UGGT1, GCKR, SLC5A1 FOLH1 2763/4885SIRT2 185/4885SIRT1 61/4885
US-20220111055-A1 MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF CETP, SLC43A1, SLC27A1 FOLH1 3754/4885SIRT2 2590/4885SIRT1 2095/4885
US-20160271082-A1 BACTERIAL EFFLUX PUMP INHIBITORS ABCB11, ABCB1, SLC47A1 FOLH1 1248/4885SIRT2 2285/4885SIRT1 2378/4885
US-11993571-B2 Indole derivatives as efflux pump inhibitors ABCB11, ABCB1, ABCG2 FOLH1 2058/4885SIRT2 1310/4885SIRT1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.